Amgen (AMGN) Says Phase 3 A.R.R.O.W. Study of Once-Weekly KYPROLIS Regimen Meet Primary Endpoint of Progression-Free Survival In R/R Multiple Myeloma Patients
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 A.R.R.O.W. trial, which showed KYPROLIS® (carfilzomib) administered once-weekly ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
